REG - FTSE Russell Mediclinic Intnl plc BlackRock Grtr Eur - Mediclinic International

Mediclinic InternationalAnnouncement

22/05/2023 18:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230522:nRSV2559Aa&default-theme=true

RNS Number : 2559A  FTSE Russell  22 May 2023

 

 Further to the FTSE notice released on 18 May 2023
 (https://research.ftserussell.com/products/index-notices/home/getnotice/?id=2607911)
 in relation to Mediclinic International (UK): Constituent Deletion,  please
 note the FTSE 250 Index replacement and any other associated index changes.

 All other details remain unchanged. Please see updated notice below:

Mediclinic International (UK): Constituent Deletion - Update

Changes in FTSE UK Index Series

22 May 2023

 Subject to court sanctioning the scheme of arrangement in relation to the cash
 offer for Mediclinic International (UK, constituent) by Manta Bidco Ltd
 (non-constituent), please see details of affected indexes and effective dates
 below:

 Mediclinic International (UK, B8HX8Z8) will be deleted from the FTSE 250
 index.

 BlackRock Greater Euro Inv Tst (UK, B01RDH7) will be added to the FTSE 250
 Index and deleted from the FTSE SmallCap Index.

 All changes effective from 25 May 2023.

 Full details of index changes available on the FTSE Russell website.

 

 

 

 

 

 

 

 For further information please contact FTSE Russell Client Services at
 info@ftserussell.com or call:

Australia  +1800 653 680
 Hong Kong  +852 2164 3333
 Japan      +81 3 6441 1430
 London     +44 (0) 20 7866 1810
 New York   +1866 551 0617

 

 Alternatively please visit our website at www.ftserussell.com

 Terms of Use (http://www.ftserussell.com/legal/website-terms-use) | Copyright
 © 2023 FTSE Russell

 

 

Alternatively please visit our website at www.ftserussell.com

Terms of Use (http://www.ftserussell.com/legal/website-terms-use) | Copyright
© 2023 FTSE Russell

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  FTSBLGDUCUDDGXD